English
Regional settings| Spread | 0.12 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 0.1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 42.51 |
| Open | 42.8 |
| 1-Year Change | 18.33% |
| Day's Range | 42.72 - 43.44 |
GlaxoSmithKline PLC is a global healthcare company. The Company researches and develops a range of products in three primary areas: Pharmaceuticals, Vaccines and Consumer Healthcare. Its product formulations include tablets, creams/ointments, inhalers, injections, liquids and sterile products. Its Pharmaceuticals business has a portfolio of established medicines in respiratory, human immunodeficiency virus (HIV), immuno-inflammation and oncology. Its Vaccines business has a portfolio of vaccines to help protect people from a range of diseases throughout their lives. Its vaccines tackle diseases, including pneumococcal disease, meningitis, hepatitis, rotavirus, whooping cough and influenza. Its Consumer Healthcare business combines science and consumer insights to create everyday healthcare brands that consumers trust, and experts recommend for oral health, pain relief, cold, flu and allergy, digestive health and vitamins, minerals and supplements.
BRIEF: For the fiscal year ended 31 December 2021, GlaxoSmithKline plc (ADR) revenues increased less than 1% to £34.11B. Net income decreased 24% to £4.39B. Revenues reflect Pharmaceuticals segment increase of 4% to £17.73B, US segment increase of 4% to £15.09B, also reflect Consumer Healthcare segment decrease of 4% to £9.61B, Vaccines segment decrease of 3% to £6.78B, Unallocated segment decrease from £28M to £0K.
Ordinary Shs. 25p Par, 05/11, 10B auth., 5,657,488,184 issd., less 494,074,284 Treas. shs. @ Cost. Insiders own 0.02%. PO: NA. 11/91, 9/89, & 2/86,2-for-1 stock splits. 2/00, Company formed through merger with SmithKline Beecham plc @ 1 ADR-for-1.138 ADS of GSK and Glaxo Wellcome plc @ 1.
